Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Short Interest Update

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) was the recipient of a large drop in short interest in December. As of December 15th, there was short interest totaling 71,326 shares, a drop of 28.7% from the November 30th total of 100,053 shares. Approximately 1.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 66,726 shares, the days-to-cover ratio is presently 1.1 days. Based on an average daily trading volume, of 66,726 shares, the days-to-cover ratio is presently 1.1 days. Approximately 1.1% of the shares of the stock are sold short.

Calidi Biotherapeutics Stock Performance

Shares of Calidi Biotherapeutics stock traded down $0.05 during mid-day trading on Monday, reaching $1.19. 167,992 shares of the stock traded hands, compared to its average volume of 483,012. The business has a 50-day moving average of $1.45 and a 200 day moving average of $2.91. Calidi Biotherapeutics has a fifty-two week low of $1.10 and a fifty-two week high of $19.20. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.12 and a quick ratio of 2.12.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($2.21) earnings per share for the quarter. As a group, analysts predict that Calidi Biotherapeutics will post -4.48 EPS for the current year.

Institutional Trading of Calidi Biotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Warberg Asset Management LLC acquired a new stake in shares of Calidi Biotherapeutics during the 3rd quarter worth approximately $28,000. Belpointe Asset Management LLC purchased a new position in shares of Calidi Biotherapeutics during the first quarter worth $141,000. Finally, Armistice Capital LLC purchased a new stake in shares of Calidi Biotherapeutics in the 1st quarter valued at $1,881,000. 12.53% of the stock is owned by institutional investors and hedge funds.

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.